82436-77-9 Usage
Chemical Properties
Suberate Bis(sulfosuccinimidyl) Sodium Salt is Off-White Solid
Uses
Different sources of media describe the Uses of 82436-77-9 differently. You can refer to the following data:
1. Suberate Bis(sulfosuccinimidyl) Sodium Salt is a water-soluble protein cross-linker for: cross-linking and targeting of mouse erythrocytes, receptor-ligand cross-linking, cross-linking of calveolin proteins, cross-linking of growth factors to proteinase inhibitor, and cross-linking of glass bead.
2. Suberic acid bis(3-sulfo-N-hydroxysuccinimide ester) sodium salt (BS3) is useful for the preparation of protein-protein, receptor-ligand and hapten carrier molecule conjugates.
General Description
Suberic acid bis(3-sulfo-N-hydroxysuccinimide ester) sodium salt (BS3) is a water soluble, homobifunctional cross-linking reagent with amine reactivity. It is typically coupled to molecules containing primary amines by amide bonds buffered at pH 7.5 (6.5-8.5). It incorporates 8-atom linker.
Check Digit Verification of cas no
The CAS Registry Mumber 82436-77-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,4,3 and 6 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 82436-77:
(7*8)+(6*2)+(5*4)+(4*3)+(3*6)+(2*7)+(1*7)=139
139 % 10 = 9
So 82436-77-9 is a valid CAS Registry Number.
InChI:InChI=1/C16H20N2O14S2/c19-11-7-9(33(25,26)27)15(23)17(11)31-13(21)5-3-1-2-4-6-14(22)32-18-12(20)8-10(16(18)24)34(28,29)30/h9-10H,1-8H2,(H,25,26,27)(H,28,29,30)
82436-77-9Relevant articles and documents
DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF
-
, (2021/10/02)
The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.